Compare Eli Lilly And Co (LLY) vs Workday Inc (WDAY) Price & Performance

Eli Lilly (LLY) trades at $1,150.86, down 2.39% on the day, with a bullish technical signal from moving averages and strong fundamental performance. The company reported robust earnings beats in recent quarters, with Q1 2026 EPS of $8.55 exceeding expectations by 23%. Revenue surged to $65.18 billion in 2025, driving a net income margin of 34.99%. Recent news highlights LLY's $2.8 billion acquisition of AtaiBeckley to expand its neuroscience pipeline, signaling strategic growth in mental health treatments.

Outlook remains positive with analyst consensus price target of $1,380 implying 20% upside, supported by 73% buy ratings. Key risks include high valuation multiples (P/E 41.89) and rising debt levels, though operating cash flow growth to $16.81 billion in 2025 provides financial flexibility. Investors should monitor Q2 2026 earnings on August 5 for continued execution on weight-loss drug demand and integration of recent acquisitions.

Workday (WDAY) trades at $146.92, up 1.48% on the day, with a bullish technical signal from moving averages and a consensus analyst price target of $151.36. The company has beaten EPS estimates for three consecutive quarters, with Q2 2026 expected at $2.62. Revenue grew to $8.45 billion in 2025, though net income margin compressed to 6.22% from 19.02% in 2024. Positive sentiment is driven by AI product expansion, but a lawsuit over AI bias and net cash outflows present headwinds.

WDAY offers growth potential with strong subscription revenue and AI-driven deal expansion, yet high P/E of 45.1 suggests premium valuation. Risks include competitive pressures, regulatory scrutiny, and reliance on enterprise spending. Analyst consensus is bullish with 55.55% buy ratings, but investors should monitor execution on profitability and legal challenges.